A different approach, using a CXCL12 knock out mouse model also resulted in enhanced targeting of AML cells by FLT3 inhibitors and chemotherapy treatment as compared to mice with normal CXCL12 expression (38). The gene discussed is CXCL12; the disease is acute myeloid leukemia.